Table 1.
Baseline characteristics of the raw and IPTW analyses in older and control patients.
| Variables | Raw analysis | IPTW analysis | ||||||
|---|---|---|---|---|---|---|---|---|
| Control group (CG) n:145 | Older group (OG) n: 116 | P | Standardized difference | Control group (CG) | Older group (OG) | P | Standardized difference | |
| Age (year) | 54.8 (2.6) | 63.3 (2.5) | <0.001 | |||||
| Sex (female %) | 89 (61.4) | 97 (83.6) | <0.001 | −0.514 | 103 (71.9) | 86 (77.6) | 0.294 | −0.133 |
| BMI (kg/m2) | 47.1 (6.5) | 45.3 (5.5) | 0.055 | −0.240 | 46.7 (6.0) | 46.2 (5.9) | 0.522 | −0.081 |
| EBW (kg) | 58.6 (17.8) | 50.0 (13.5) | <0.001 | −0.428 | 56.1 (15.8) | 54.5 (15.4) | 0.457 | −0.090 |
| ASA | 2.4 (0.5) | 2.5 (0.5) | 0.377 | 0.110 | 2.50 (0.5) | 2.4 (0.5) | 0.669 | −0.053 |
| Current smoker (%) | 29 (20.0) | 4 (3.4) | <0.001 | 0.532 | 18 (12.6) | 8 (7.4) | 0.181 | −0.046 |
| Type 2 DM (%) | 63 (43.4) | 62 (53.4) | 0.108 | 0.201 | 69 (48.0) | 51 (45.6) | 0.711 | −0.026 |
| Duration DM (year) | 8.2 (3.8) | 9.3 (6.7) | 0.442 | 0.094 | 8.9 (4.7) | 8.7 (5.9) | 0.609 | −0.064 |
| Insulin treatment (%) | 3 (2.1) | 8 (6.9) | 0.053 | 0.234 | 5 (3.1) | 5 (4.3) | 0.624 | 0.061 |
| AHT (%) | 108 (74.5) | 92 (79.3) | 0.359 | 0.114 | 109 (76.1) | 88 (79.0) | 0.581 | 0.069 |
| Duration AHT (year) | 9.8 (6.4) | 11.1(6.5) | 0.077 | 0.221 | 10.7 (5.5) | 10.7 (5.5) | 0.872 | 0.020 |
| Anti-AHT drugs: >3 (%) | 28 (19.3) | 19 (16.4) | 0.540 | −0.097 | 24 (16.8) | 19 (17.3) | 0.925 | 0.011 |
| Dyslipidemia (%) | 68 (46.9) | 62 (53.4) | 0.292 | 0.131 | 70 (478.9) | 55 (49.5) | 0.918 | 0.012 |
| SAHS (%) | 59 (40.7) | 40 (34.5) | 0.304 | −0.128 | 57 (39.6) | 38 (34.0) | 0.358 | −0.116 |
Data are mean (SE); BMI: body mass index; EBW: excess body weight; ASA: American Society of Anesthesiologists Score; DM: diabetes mellitus; AHT: arterial hypertension; SAHS: sleep apnea hypopnea syndrome.